Flputnam Investment Management Co. Sells 1,232 Shares of Stryker Co. (NYSE:SYK)

Flputnam Investment Management Co. reduced its stake in Stryker Co. (NYSE:SYK) by 4.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,117 shares of the medical technology company’s stock after selling 1,232 shares during the period. Flputnam Investment Management Co.’s holdings in Stryker were worth $8,121,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Keybank National Association OH lifted its stake in shares of Stryker by 3.5% during the 3rd quarter. Keybank National Association OH now owns 27,823 shares of the medical technology company’s stock worth $7,603,000 after purchasing an additional 952 shares during the last quarter. Carnegie Capital Asset Management LLC grew its holdings in Stryker by 0.5% in the fourth quarter. Carnegie Capital Asset Management LLC now owns 96,241 shares of the medical technology company’s stock worth $28,820,000 after purchasing an additional 497 shares during the last quarter. CoreCap Advisors LLC lifted its holdings in shares of Stryker by 3.9% during the 4th quarter. CoreCap Advisors LLC now owns 5,030 shares of the medical technology company’s stock valued at $1,506,000 after purchasing an additional 191 shares during the last quarter. DNB Asset Management AS boosted its position in shares of Stryker by 5.7% in the 4th quarter. DNB Asset Management AS now owns 76,413 shares of the medical technology company’s stock worth $22,883,000 after purchasing an additional 4,143 shares in the last quarter. Finally, LGT Capital Partners LTD. grew its stake in Stryker by 24.4% during the 4th quarter. LGT Capital Partners LTD. now owns 434,997 shares of the medical technology company’s stock worth $130,264,000 after buying an additional 85,240 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In related news, Director Allan C. Golston sold 3,273 shares of the stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the transaction, the director now owns 14,242 shares of the company’s stock, valued at $4,856,522. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 201,146 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $342.90, for a total value of $68,972,963.40. Following the transaction, the director now owns 3,755,128 shares in the company, valued at approximately $1,287,633,391.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 212,109 shares of company stock worth $72,845,768. 5.50% of the stock is currently owned by corporate insiders.

Stryker Trading Down 0.9 %

Shares of NYSE SYK traded down $3.09 during mid-day trading on Tuesday, reaching $336.04. 286,195 shares of the company’s stock were exchanged, compared to its average volume of 1,240,804. The firm has a market capitalization of $127.85 billion, a price-to-earnings ratio of 41.11, a PEG ratio of 2.75 and a beta of 0.89. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $361.41. The company’s 50-day moving average is $350.75 and its 200-day moving average is $311.41. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share for the quarter, beating analysts’ consensus estimates of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The business had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same period last year, the business earned $3.00 earnings per share. The business’s revenue for the quarter was up 11.8% on a year-over-year basis. Analysts expect that Stryker Co. will post 11.86 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 0.95%. The ex-dividend date is Wednesday, March 27th. Stryker’s dividend payout ratio (DPR) is presently 38.79%.

Analyst Ratings Changes

SYK has been the subject of several recent analyst reports. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. TD Cowen upped their price target on shares of Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Wells Fargo & Company lifted their price objective on shares of Stryker from $336.00 to $364.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 31st. Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and set a $360.00 price target for the company in a research report on Wednesday, January 31st. Finally, Roth Mkm increased their price objective on Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $339.22.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.